Immunotherapies have permanently changed the landscape of cancer therapy and there may be a continued expansion of the indications, complexity and targets leveraged to treat cancers, according to papers published Jan. 12 in JACC: CardioOncology.

In one paper, Lili Zhang, MD, ScM, FACC, et al., summarize the published data on the epidemiology, diagnosis and management of cardiotoxicity of immune checkpoint inhibitors (ICIs). In a separate Viewpoint, Franck Thuny, MD, PhD, et al., outline the French Working Group's approach for ICI cardiovascular monitoring and explain how ICI-induced myocarditis is one of the most serious complications of cancer treatment. Read more.

To reinforce learning on this topic, JACC: CardioOncology Editor-in-Chief Bonnie Ky, MD, MSCE, FACC, et al., recorded a discussion examining a patient case depicting early immune checkpoint inhibitor cardiotoxicity. Watch now.